Clinical Features and Outcomes of Hospitalized Solid Organ Transplant and Hematopoietic Stem Cell Recipients with Sars-CoV-2 Infection in the Midwestern United States: A Multi-Center Retrospective Cohort Study
1Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, 2University of Nebraska Medical Center, Omaha, NE, 3Cleveland Clinic, Cleveland, OH, 4University of Kansas Medical Center, Overland Park, KS, 5Infectious Diseases, Indiana University, Indianapolis, IN, 6Infectious Diseases, University of Chicago, Chicago, IL, 7University of Chicago, Chicago, IL, 8Northwestern University Comprehensive Transplant Center, Chicago, IL
Meeting: 2022 American Transplant Congress
Abstract number: 694
Keywords: COVID-19, Infection, Lung infection, Viral therapy
Topic: Clinical Science » Infection Disease » 24 - All Infections (Excluding Kidney & Viral Hepatitis)
Session Information
Session Name: All Infections (Excluding Kidney & Viral Hepatitis) I
Session Type: Poster Abstract
Date: Saturday, June 4, 2022
Session Time: 5:30pm-7:00pm
Presentation Time: 5:30pm-7:00pm
Location: Hynes Halls C & D
*Purpose: Immunocompromised hosts are at risk for severe complications or death from SARS-CoV-2 infection. Few studies describe the clinical features, outcomes and treatment strategies in this population across multiple sites.
*Methods: A multi-center retrospective analysis from academic medical centers in the Midwestern US was conducted for hospitalized patients with SARS-CoV-2 infection. Data was collected electronically using standardized intake and 28-day follow up case report forms. The centers included Northwestern University, University of Nebraska, Cleveland Clinic, University of Chicago, Indiana University and University of Kansas.
*Results: The cohort included 272 patients hospitalized from March 2020 to November 2021. Demographics are in Table 1. Mean admission was 6.84 ± 6.42 days after symptom onset. The most commonly reported symptoms were cough (71.4%), dyspnea (59.6%), fatigue (55.3%), fever (54.9%), and diarrhea (43.9%). Admission CXR had pneumonia in 31.6%; 63% with multifocal or patchy opacities. 87 patients had a chest CT; 72 (82.7%) showed pneumonia. 97 patients (36.1%) required ICU admission. Treatments included remdesivir (58.5%), dexamethasone (54.4%), convalescent plasma (3.0%), IL-6 inhibitor (4.5%). Immunosuppression management included holding (44.2%) or decreasing (26.6%) the dose of antimetabolite. 76 patients (28.3%) had documented bacterial co-infection, in blood (34.1%), lung (30.6%) and urine (30.6%). 6 (2.2%) patients experienced rejection within 30 days and 8 patients (3.0%) developed CMV viremia. 26 patients (9.7%) died by day 28.
*Conclusions: This cohort had high rates of ICU admission (36.1%), bacterial co-infection (28.3%), rehospitalization (31.5%) and mortality (9.7%).
To cite this abstract in AMA style:
Tanna S, Florescu D, Majeed A, Banzon J, Waller S, Eid A, Baertl NBarros, Friedman D, Mullane K, Ison M. Clinical Features and Outcomes of Hospitalized Solid Organ Transplant and Hematopoietic Stem Cell Recipients with Sars-CoV-2 Infection in the Midwestern United States: A Multi-Center Retrospective Cohort Study [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/clinical-features-and-outcomes-of-hospitalized-solid-organ-transplant-and-hematopoietic-stem-cell-recipients-with-sars-cov-2-infection-in-the-midwestern-united-states-a-multi-center-retrospective-coh/. Accessed May 18, 2025.« Back to 2022 American Transplant Congress